The effects of GLP-1 in Maturity- onset diabetes of the young (MODY)

Signe H. Østoft, Diabetes Research Division0 个研究点开始时间: 2012年7月10日最近更新: 2015年12月14日

试验速览

暂无简介。

•Caucasian above 18 years of age
•Well characterised MODY3
•Body mass index (BMI) >19 kg/m2
•Normal haemoglobin (males >8.2 mM, females >7.2 mM)
•Normal blood pressure (<160/100 mmHg)
•Informed consent
•Capability to perform a light cycling test (heart rate 100-120 beats per minute during 30 minutes)
•Females: use of anticonception (IUC or hormonal)
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 14
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 2

•Heart failure: New York Heart Association class III-IV
•Uraemia, end-stage renal disease, or any other cause of impaired renal function with s-creatinine >130 µM and/or albuminuria
•Liver disease (alanine amino transferase (ALAT) and/or aspartate amino transferase (ASAT) >2 × upper normal serum levels)
•Acute or chronic pancreatitis
•Struma or thyroid cancer
•Pregnancy or breast feeding
•Inability to complete the study
•Treatment naïve patients with HbA1c <7.0 %
•Treatment with medicine that can not be paused for 12 hours
•Known allergic reaction to study medication
•Intention to become pregnant
•Unwillingness to complete the protocol

发起方

Signe H. Østoft, Diabetes Research Division